Abstract
Antigen-specific vaccines are one of several molecularly targeted approaches under investigation as possible treatments for prostate cancer. Important to the development of vaccines is the identification of appropriate target antigens. We hypothesized that antigens of the prostate might be identified in patients with the chronic prostatitis/pelvic pain syndrome, a syndrome for which an autoimmune pathology has been proposed. Such antigens might represent naturally recognized target antigens of the prostate that could be investigated in the future as prostate tumor antigens. In this report, we used SEREX to identify proteins expressed in a prostate cDNA expression library recognized by IgG from the sera of patients with chronic prostatitis. Candidate proteins were evaluated using a panel of sera from 62 subjects with symptomatic prostatitis and 71 control male blood donors. We identified one protein that was recognized primarily in sera from subjects with prostatitis compared with controls. MAD-PRO-34, a nucleolar autoantigen, was recognized in 6/62 subjects and 0/71 controls (p = 0.00897). This protein had previously been identified as an autoantigen in patients with prostate cancer. In addition, the NY-CO-7 protein was recognized in 9/62 subjects and 3/71 controls (p = 0.0654). Two subjects had IgG specific for both the MAD-PRO-34 and NY-CO-7 gene products. Our results demonstrate that some patients with the chronic prostatitis/pelvic pain syndrome have autoantibodies to specific proteins. Proteins identified, and MAD-PRO-34 in particular, could be further investigated as potential prostate tumor antigens.
Article PDF
Similar content being viewed by others
REFERENCES
McNeel DG, Disis ML: Tumor vaccines for the management of prostate cancer. Arch Immunol Ther Exp 48:85–93, 2000
Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53:260–266, 1999
Meidenbauer N, Harris DT, Spitler LE, Whiteside TL: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43:88–100, 2000
Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG: Dendritic cell-based Xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167:7150–7156, 2001
Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlovic S: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6:2175–2182, 2000
Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 38:208–217, 2000
Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL: Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39:54–59, 1999
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: Agene encoding an antigen rec-ognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647, 1991
Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489–495, 1993
Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270, 1998
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458–6462, 1994
Kawakami Y, Rosenberg SA: Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol 14:173–192, 1997
Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A: Induction of primary NY-ESO-1 im-munity: CD8 +T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 +cancers. Proc Natl Acad Sci USA 97:12198–12203, 2000
Ponniah S, Arah I, Alexander RB: PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 44:49–54, 2000
Zisman A, Zisman E, Lindner A, Velikanov S, Siegel YI, Mozes E: Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J Urol 154:1052–1055, 1995
McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML: Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164:1825–1829, 2000
McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML: Naturally occurring prostate cancer antigen-specific Tcell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 47:222–229, 2001
Klyushnenkova EN, Ponniah S, Rodriguez A, Kodak J, Mann DL, Langerman A, Nishimura MI, Alexander RB: CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother 27:136–146, 2004
True LD, Berger RE, Rothman I, Ross SO, Krieger JN: Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: A prospective biopsy study. J Urol 162:2014–2018, 1999
Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M: Chronic prostatitis: A thorough search for etiologically involved microorganisms in 1,461 patients. Infection 19:S119–S125, 1991
John H, Barghorn A, Funke G, Sulser T, Hailemariam S, Hauri D, Joller-Jemelka H: Noninflammatory chronic pelvic pain syndrome: Immunological study in blood, ejaculate and prostate tissue. Eur Urol 39:72–78, 2001
John H, Maake C, Barghorn A, Zbinden R, Hauri D, Joller-Jemelka HI: Immunological alterations in the ejaculate of chronic prostatitis patients: Clues for autoimmunity. Andrologia 35:294–299, 2003
Alexander RB, Brady F, Ponniah S: Autoimmune prostatitis: Evidence of T cell reactivity with normal prostatic proteins. Urology 50:893–899, 1997
Batstone GR, Doble A, Gaston JS: Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin Exp Immunol 128:302–307, 2002
Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA: Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: Implications for prostate cancer therapy. J Immunol 159:472–480, 1997
Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810–11813, 1995
Ochs RL, Stein TW, Jr., Chan EK, Ruutu M, Tan EM: cDNA cloning and characterization of a novel nucleolar protein. Mol Biol Cell 7:1015–1024, 1996
Fossa A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fossa SD, Paus E, Smeland EB, Gaudernack G: Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer. Br J Cancer 83:743–749, 2000
Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ: Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76:652–658, 1998
Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG: Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100:2123–2131, 2002
Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P: Naturally occurring human lymphocyte antigen-A2 restricted CD8 +T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60:4499–4506, 2000
Tureci O, Sahin U, Pfreundschuh M: Serological analysis of human tumor antigens: Molecular definition and implications. Mol Med Today 3:342–349, 1997
Tureci O, Sahin U, Zwick C, Neumann F, Pfreundschuh M: Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma 18:23–28, 1999
Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J, Patterson C: CHIP is a U-box-dependent E3 ubiquitin ligase: Identification of Hsc70 as a target for ubiquitylation. J Biol Chem 276:42938–42944, 2001
Bocker T, Bittinger A, Wieland W, Buettner R, Fauser G, Hofstaedter F, Ruschoff J: In vitro and ex vivo expression of nu-cleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate. Mod Pathol 8:226–231, 1995
Kallakury BV, Sheehan CE, Rhee SJ, Fisher HA, Kaufman RP, Jr., Rifkin MD, Ross JS: The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocar-cinoma: A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 85:1569–1576, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dunphy, E.J., Eickhoff, J.C., Muller, C.H. et al. Identification of Antigen-Specific IgG in Sera from Patients with Chronic Prostatitis. J Clin Immunol 24, 492–502 (2004). https://doi.org/10.1023/B:JOCI.0000040920.96065.5a
Issue Date:
DOI: https://doi.org/10.1023/B:JOCI.0000040920.96065.5a